COVID-19's omicron variant spelled trouble in multiple ways.
It is highly transmissible. It weakened vaccines' defense against infection, though the shots still confer strong protection against severe illness. In addition, two of three widely used monoclonal antibody treatments for those infected with it are essentially ineffective.
The virus's ability to surprise requires a medical arsenal that adapts nimbly as well. Given that, it's time for the World Health Organization (WHO) and other officials to take a fresh look at a historic infectious disease treatment — convalescent plasma.
